A comparative study of the synergism effect of Xenogan capsule and Chlorella algae tablets with metformin and vitamin E in the treatment of patients with Non-alcoholic fatty liver

A comparative study of the synergism effect of Xenogan capsule and Chlorella algae tablets with metformin and vitamin E in the treatment of patients with Non-alcoholic fatty liver - a single-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221018056221N1

Enrollment

Registered

2023-01-18

Start date

2023-01-10

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcohlic fatty liver disease. Other diseases of liver

Interventions

Intervention 1: In the first intervention group, 1000 mg metformin tablets and 400 units of vitamin E capsules (pharmaceutical company...) are prescribed daily for 12 month. Intervention 2: In the sec

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Informed consent Patients with fatty liver (grade 1-3) High liver enzymes AST, ALT (more than 4-35 IU/L)

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding being an alcoholic History of biliary diseases, heart and blood vessels, liver diseases, kidney failure and bleeding peptic ulcer, types of cancer, thyroid The presence of gastrointestinal ulcers Taking any herbal supplements and vitamins

Design outcomes

Primary

Measure	Time frame
Liver enzymes (AST, ALT, ALP). Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Tri glyceride. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Total cholesterol. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Plasma insulin levels. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Blood sugar. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Bilirubin. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Antioxidant level in blood serum. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Serum albumin. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.	—

Measure

Time frame

Liver enzymes (AST, ALT, ALP). Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Tri glyceride. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Total cholesterol. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Plasma insulin levels. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Blood sugar. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Bilirubin. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Antioxidant level in blood serum. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.;Serum albumin. Timepoint: The beginning of the study and the end of the twelfth week. Method of measurement: Using a blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahab Bazvandi

Kermanshah University of Medical Sciences

Bazvandishahab19@gmail.com+98 83 3427 4618

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026